PSP Research LLC Acquires Shares of 31,762 Denali Therapeutics Inc. $DNLI

PSP Research LLC purchased a new position in Denali Therapeutics Inc. (NASDAQ:DNLI) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 31,762 shares of the company’s stock, valued at approximately $524,000.

Several other institutional investors also recently bought and sold shares of DNLI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Denali Therapeutics by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company’s stock worth $1,210,000 after buying an additional 3,432 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Denali Therapeutics by 58.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock worth $22,732,000 after buying an additional 614,555 shares during the period. Empowered Funds LLC lifted its holdings in Denali Therapeutics by 11.0% during the first quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock worth $281,000 after buying an additional 2,052 shares during the period. Woodline Partners LP lifted its holdings in Denali Therapeutics by 13.5% during the first quarter. Woodline Partners LP now owns 113,517 shares of the company’s stock worth $1,543,000 after buying an additional 13,517 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Denali Therapeutics by 1.7% during the second quarter. JPMorgan Chase & Co. now owns 191,613 shares of the company’s stock worth $2,681,000 after buying an additional 3,210 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Trading Down 1.7%

NASDAQ DNLI opened at $18.09 on Wednesday. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01. The firm has a market cap of $2.87 billion, a PE ratio of -6.28 and a beta of 0.99. The company has a 50 day moving average price of $19.93 and a 200 day moving average price of $19.02. Denali Therapeutics Inc. has a 52 week low of $12.58 and a 52 week high of $23.77.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same quarter in the prior year, the business posted ($0.78) EPS. As a group, sell-side analysts forecast that Denali Therapeutics Inc. will post -2.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Jefferies Financial Group restated a “buy” rating and set a $40.00 target price on shares of Denali Therapeutics in a report on Monday, March 2nd. Stifel Nicolaus upped their target price on Denali Therapeutics from $34.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Leerink Partners reduced their price objective on shares of Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, April 22nd. BTIG Research reiterated a “buy” rating and set a $39.00 price objective on shares of Denali Therapeutics in a research note on Monday, May 11th. Finally, Morgan Stanley reduced their price objective on shares of Denali Therapeutics from $42.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.